As of 2025-10-24, the Relative Valuation of BridgeBio Pharma Inc (BBIO) is (50.36) USD. This relative valuation is based on P/E multiples. With the latest stock price at 53.81 USD, the upside of BridgeBio Pharma Inc based on Relative Valuation is -193.6%.
The range of the Relative Valuation is (40.29) - (60.43) USD.
Note: valuation result may not be accurate due to the low predictability of business.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | 9.9x - 14.9x | 12.4x |
| Fair Price | (40.29) - (60.43) | (50.36) |
| Upside | -174.9% - -212.3% | -193.6% |
| Date | P/E |